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The lipopolysaccharide (LPS) and O-antigen polysaccharide capsule structures of
Francisella tularensis play significant roles in helping these highly virulent bacteria avoid
detection within a host. We previously created pools of F. tularensis mutants that we
screened to identify strains that were not reactive to a monoclonal antibody to the
O-antigen capsule. To follow up previously published work, we characterize further
seven of the F. tularensis Schu S4 mutant strains identified by our screen. These
F. tularensis strains carry the following transposonmutations: FTT0846::Tn5, hemH::Tn5,
wbtA::Tn5, wzy::Tn5, FTT0673p/prsA::Tn5, manB::Tn5, or dnaJ::Tn5. Each of these
strains displayed sensitivity to human serum, to varying degrees, when compared
to wild-type F. tularensis Schu S4. By Western blot, only FTT0846::Tn5, wbtA::Tn5,
wzy::Tn5, and manB::Tn5 strains did not react to the capsule and LPS O-antigen
antibody 11B7, although the wzy::Tn5 strain did have a single O-antigen reactive band
that was detected by the FB11 monoclonal antibody. Of these strains, manB::Tn5 and
FTT0846 appear to have LPS core truncations, whereas wbtA::Tn5 and wzy::Tn5 had
LPS core structures that are similar to the parent F. tularensis Schu S4. These strains
were also shown to have poor growth within human monocyte derived macrophages
(MDMs) and bonemarrow derivedmacrophages (BMDMs). We examined the virulence of
these strains in mice, following intranasal challenge, and found that each was attenuated
compared to wild type Schu S4. Our results provide additional strong evidence that LPS
and/or capsule are F. tularensis virulence factors that most likely function by providing
a stealth shield that prevents the host immune system from detecting this potent
pathogen.
Keywords: Francisella tularensis, O-antigen, capsule, transposon mutagenesis, innate immunity, intracellular
growth, mouse virulence
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Introduction
Francisella tularensis is the causative agent of the human disease
tularemia. This small Gram negative organism is able to cause
disease with as few as 10 colony forming units (CFU) when
inhaled, and without treatment, upwards of 60% of those infected
may die (Saslaw et al., 1961; Tarnvik and Berglund, 2003; Oyston,
2008). Due to the ease of aerosolization, low infectious dose,
and potentially high fatality rates, the Center for Disease Control
and Prevention (CDC) has classified F. tularensis has a Tier I
select agent (Center for Disease Control and Prevention, 2013).
Although, there are relatively few naturally acquired Francisella
infections per year in the United States (Carvalho et al., 2014), a
primary concern is that the organismwill be used in a bioterrorist
attack. This is not an unfounded concern as Francisella species
were weaponized by Japan, United States, and the former
U.S.S.R., during and after World War II (Oyston et al., 2004;
Sjostedt, 2007). These concerns have highlighted the need to
develop a vaccine to prevent disease and associated deaths from
the potential use of Francisella as a bioterrorist weapon.
Although essential genes for bacterial growth and replication
have been identified as important for Francisella to cause
productive infection, few other genes have been clearly linked
to pathogenesis. Our studies of F. tularensis waaY and waaL
mutants have previously demonstrated that LPS associated O-
antigen and capsule have significant roles in the pathogenesis
of F. tularensis Schu S4 (Lindemann et al., 2011; Rasmussen
et al., 2014). These genes function in LPS assembly by
participating in the LPS core construction (waaY) and in
ligating the tetrasaccharide O-antigen repeats to LPS core (waaL)
(Rasmussen et al., 2014). In addition, a number of other
labs have shown that strain with mutations in genes that are
involved in capsule and LPS biosynthesis have significantly
altered virulence properties (Sandstrom et al., 1988; Comstock
and Kasper, 2006; McLendon et al., 2006; Barker and Klose,
2007; Su et al., 2007; Weiss et al., 2007; Apicella et al., 2010).
Strains carrying mutations in either of these genes enter into
human MDMs at elevated levels, are cytotoxic for MDMs at
early time points, and are much more sensitive to human serum
than the parent Schu S4 strain (Lindemann et al., 2011). These
data suggest that one of the significant functions of the O-
antigen structures of both the Francisella LPS and capsule are
to provide stealth concealment for the organism, allowing it
to avoid detection by the host. This is not a novel strategy
to avoid host recognition, as it has been described in some
detail for other Gram-negative organisms (Comstock andKasper,
2006). Interestingly, even though the waaY or waaL mutants
lack O-antigen and capsule and are hypercytotoxic in MDMs
(Lindemann et al., 2011), these strains still disseminate to the
livers and spleens of mice during infection but cause death by
a different mechanism than wild type F. tularensis (Rasmussen
et al., 2014). These data imply that F. tularensis expresses
antigens that can induce host inflammation, but that they are
obscured by the LPS and capsule in wild type organisms. The
virulence still possessed by the F. tularensis O-antigen mutants
is unusual since O-antigen mutants in other species of bacteria
are typically avirulent (Rietschel, 1984; Iredell et al., 1998; Prior
et al., 2003; Ho and Waldor, 2007; Sheng et al., 2008; Post et al.,
2012).
An interesting aspect of the F. tularensis capsule is that
the polysaccharide repeat structure is exactly the same as the
LPS O-antigen (Vinogradov et al., 2002; Thomas et al., 2007;
Apicella et al., 2010; Wang et al., 2011). While the O-antigen
structure is the same, F. tularensis capsule is assembled without
core LPS sugars, 2-keto-3-deoxyoctulsonic acid (KDO), or lipid
A (Apicella et al., 2010). Due to the identical tetrasaccharide
repeat containing acetimido sugars and high molecular weight
structure, F. tularensis capsule is considered to be a Group
4 capsule (Whitfield, 2006). Studies of Group 4 capsules
in other organisms have revealed distinct LPS and capsule
biosynthetic pathways (Whitfield, 2006). To date, however,
divergent biosynthetic pathways for F. tularensis LPS and capsule
have not been discovered. Although extensive analysis of O-
antigen biosynthesis has not been done in Francisella, LVS strains
with mutations in the wbt genes do not produce O-antigen
(Raynaud et al., 2007). In addition, wbt mutant strains are also
more susceptible to complement-mediated lysis than F. tularensis
LVS (Li et al., 2007; Clay et al., 2008). Strains carrying either
a waaY or waaL mutation display moderate attenuation in an
intranasal infection (i.n.) as seen by the 1000-fold and 100-
fold increase in the LD50, respectively (Rasmussen et al., 2014),
compared to the F. tularensis Schu S4 theoretical LD50 of ∼1
CFU (Kim et al., 2012). When infected intraperitoneally (i.p.) the
mutants are significantly attenuated (more than a 100,000 fold
increase in comparison to the wild type LD100 of ∼1 CFU), as
would be expected for traditional waamutants (Rietschel, 1984).
We screened a F. tularensis Schu S4 mutant library of ∼7500
mutants by enzyme-linked immunosorbent assay (ELISA) to
identify strains defective for capsule production (Rasmussen
et al., 2014). From that screen we identified six strains with
mutations in genes FTT0846, FTT1138 (hemH), FTT1236
(waaY), FTT1238c (waaL), FTT1464c (wbtA), and FTT1458c
(wzy) that had significantly less capsule compared to the parent
strain, as detected by a lack of binding to the anti-capsule mAb
(11B7) (Rasmussen et al., 2014). Mutation of these genes also
caused decreased binding of the anti-O-antigen mAb (FB11)
as detected by ELISA (Rasmussen et al., 2014). In a second
screen, we identified three additional mutant strains FTT1447c
(manB), FTT1512c (dnaJ) and an intergenic insertion between
FTT0673 and FTT0674c (prsA) that also had decreased amounts
of detectable capsule.
Although we have previously characterized the F. tularensis
waaY and waaL mutants in some detail, this manuscript
describes our work characterizing the additional F. tularensis
strains with O-antigen defects that map to dnaJ, hemH, manB,
wbtA,wzy, FTT0846, and FTT0673p/prsAp::Tn5.We present data
on the serum sensitivity of these strains, characteristics of the
capsule/O-antigen and LPS core of each strains, the ability to
grow in murine bone marrow derived macrophages and human
macrophages, and attenuation for virulence in a murine infection
model. We have found that mutations in dnaJ, hemH, and the
FTT0673p/prsAp::Tn5 strain did not have significant differences
in many of the assays performed, whereas the strains with
mutations inmanB, wzy, wbtA, and FTT0846 display phenotypes
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similar to those observed for the F. tularensis waaY and waaL
mutants.
Materials and Methods
Bacterial Strains, Plasmid Construction, and
Growth Conditions
F. tularensis subsp. tularensis Schu S4 was routinely cultured on
Modified Mueller Hinton (MMH) plates (Acumedia, Lansing,
MI) or in MMH broth. Schu S4 mutant strains were grown
on MMH plates supplemented with 50µg/ml of kanamycin as
needed. Complementation was performed by cloning the coding
sequence of a gene downstream of the constitutive Pgro promoter
into pTrc99A. Primers used to amplify functional wzy andmanB
genes for complementation are respectively, wzy: Forward, 5′-
GGATCCGGTACCGTGTACATAAAAAAAGTGTCTTTTAAA
ATT-3′ and Reverse, 5′-GTCGACAAGGTTTATTATTAAATGT
ACAAACC-3′. manB: Forward, 5′-GGATCCGGTACCAT
GAGACAAACTATAATAAAAGAAATAATC-3′ and Reverse,
5′-GTCGACAGAAAGTTAGGGAATATTTTTGACTG-3′. The
promoter-gene construct was then cloned into the Francisella
shuttle vector, pBB103 (Buchan et al., 2008) and cryotransformed
into mutant strains as previously described (Buchan et al., 2008).
Complemented strains were grown on MMH plates or in MMH
broth supplemented with 50µg/ml of spectinomycin. All work
with F. tularensis Schu S4 was performed within the Carver
College of Medicine Biosafety Level 3 (BSL3) Core Facility
and experimental protocols were reviewed for safety by the
BSL3 Oversight Committee of The University of Iowa Carver
College of Medicine. Recombinant DNA work with F. tularensis
Schu S4 was reviewed and approved by the University of Iowa
Institutional Biosafety Committee.
In Vitro Growth Assay
To determine whether F. tularensis mutant strains exhibited
growth defects compared to wild type Schu S4, wild type and
mutants were grown to saturation with shaking at 37◦C and
diluted into fresh MMH broth to an OD600 of 0.1. Broth cultures
were shaken at 200 rpm at 37◦C, and the optical density was
determined at intervals. The doubling time (T) was calculated
using the formula N = Nkt0e, where T = (ln 2)/k, and growth
indices were calculated by taking the same time points in the
linear range for comparison (t is time, N is the amount after t,
N0 is the initial amount, and k is the constant rate of growth).
Serum Sensitivity Assay
After obtaining informed consent, human serum was obtained
from 15 to 20 individuals with no known history of tularemia
and then pooled following the protocol (#200307026) approved
by the Institutional Review Board (IRB) for human subjects of
the University of Iowa. Bacteria were grown in MMH broth
(with 50µg/ml of spectinomycin for complemented mutants)
for ∼18 h at 200 rpm at 37◦C. Bacteria were quantitated by
measuring the OD600. Bacteria were added to PBS to make a
culture of 1 × 107 CFU/ml in 50% pooled normal human serum
and incubated with shaking at 37◦C for 90min. Before and after
incubation, bacteria were serially diluted in PBS, plated onMMH
plates (with spectinomycin as needed), and grown for 2 days at
37◦C with 5% CO2. Strains were serially diluted and plated for
inputs and also after serum treatment to determine percentage of
survivability.
PAGE, Immunoblotting and Emerald Green Stain
of Bacterial Whole Cell Lysates
Francisella strains from freshly streaked agar plates were
inoculated into MMH broth and grown for 24 h before the
OD600 was measured and recorded. One ml broth cultures
were centrifuged at 8000x g for 1min before the pellet was
resuspended in Buffer Part A, [6mM Tris, 10mM EDTA, and
2% (wt/vol) SDS (pH 6.8)] and heated to 65◦C to sterilize
cultures. Bacterial lysates were incubated with proteinase K
(New England Biolabs, Ipswitch, MA) at 37◦C for 24 h before
lyophilizing. Approximately 5µg of bacterial material from
each sample was mixed with NuPage (Life Technologies,
Carlsbad, CA) sample reducing agent and buffer, boiled for
10min, and loaded into a 4–12% Bis-Tris NuPage gel and
separated by electrophoresis using NuPage MES SDS running
buffer (Life Technologies, Carlsbad, CA). For immunoblots,
samples separated by PAGE were transferred to nitrocellulose
using a semi-dry transfer system (Bio-Rad, Hercules, CA). The
nitrocellulose membrane was blocked in blocking buffer (5% BSA
in PBS) and then incubated with either primary mAb 11B7 (Dr.
Apicella, University of Iowa, IA) to detect capsule, or mAb FB11
to detect LPSO-antigen (QEDBioscience, San Diego, CA). Bands
were visualized using goat anti-mouse IgG (H+ L) conjugated to
horseradish peroxidase (Jackson ImmunoResearch, West Grove,
PA) and SuperSignal West Pico chemiluminescent substrate
(Pierce Biotechnology, Rockford, IL). The ProQ-Emerald 300
stain was used to visualize carbohydrates and the protocol
was followed according to the instructions of the manufacturer
(Invitrogen, Waltham, MA).
Isolation and Culture of Human and Murine
Macrophages
Venous blood was drawn from healthy adult volunteers using
a protocol approved by The University of Iowa Institutional
Review Board (IRB) for Human Subjects at the University of
Iowa, and all subjects provided informed consent. Peripheral
blood mononuclear cells (PBMCs) were isolated as described
previously (Schulert and Allen, 2006). Briefly, PBMCs were
isolated from venous blood by centrifugation on Ficoll-
Hypaque (GE Healthcare, Piscataway, NJ), washed twice in
HEPES-buffered RPMI 1640 with L-glutamine (RPMI) (Lonza,
Walkersville, MD), seeded into Teflon jars at 2 × 106 cells/ml,
and allowed to differentiate into MDMs for 5 to 7 days in RPMI
1640 plus 20% autologous serum at 37◦C with 5% CO2.
To isolate BMDMs, 6–8 week old BALB/c female mice
were purchased from Frederick National Cancer Institute (NCI,
Frederick, MD) and femurs were harvested and flushed with
Dulbecco’s modified Eagle medium (DMEM, Life Technologies,
Carlsbad, CA). Cells were grown in DMEM with 20% L929
cell-conditioned media, 10% heat-inactivated fetal bovine serum
(FBS, Life Technologies, Carlsbad, CA) and supplemented with
100µg/ml of streptomycin and 100 U/ml of penicillin. Cells were
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incubated at 37◦C with 5% CO2 for 5–7 days until monolayers of
macrophages were detected.
Human and Murine Intramacrophage Growth
To quantify the extent of intracellular replication, MDMs were
plated in Costar 24-well dishes (Sigma-Aldrich, St. Louis, MO) at
a density of 1–2×105 cells/well and allowed to adhere overnight
at 37◦C. Monolayers were washed with warm PBS twice, and
infected in duplicate or triplicate with unopsonized wild-type
Schu S4 or mutant strains in RPMI plus 2.5% heat-inactivated
(56◦C, 30min) pooled human serum at an MOI of 100:1. After
1 h at 37◦C, monolayers were washed three times with PBS to
remove extracellular bacteria, and fresh RPMI plus 2.5% heat
inactivated normal human serum was added. Wells were lysed
in 0.5% saponin at 1, 16, and 24 h post-infection. Lysates were
serially diluted in PBS, and viable bacteria were enumerated by
plating on MMH agar as described above. BMDM infections
using the appropriate media were done similarly to the human
MDM infections. BMDMs were plated at a density of 3 × 105
cells/well and infected at an MOI of 100:1.
Confocal Microscopy
Macrophages infected with F. tularensis were processed for
microscopic analysis as previously described (Allen and Aderem,
1996) with minor modifications. Cells were fixed in 10%
formalin, permeabilized by the addition of -20◦C acetone
and methanol (1:1), and blocked at 4◦C for 5 days in PBS
plus 0.5mg/ml sodium azide, 5mg/ml BSA (Thermo Fisher
Scientific, Waltham, MA) and 10% horse serum (Thermo Fisher
Scientific, Waltham, MA). Parallel samples were lysed and
examined for sterility so that experimental samples could be
removed from the BSL-3 facility. The rabbit anti-F. tularensis
antiserum (BD Diagnostics, Franklin Lakes, NJ) and Dyelight
549-conjugated goat anti-rabbit IgG F(ab′)2 secondary antibody
from Jackson Immuno Research Laboratories (West Grove, PA)
were used to detect wild type and mutant strains. The late
endosome/lysosome-associated membrane protein-1 (lamp-1)
was detected using a mouse anti-human lamp-1 monoclonal
antibody (H4A3) from the Developmental Studies Hybridoma
Bank at the University of Iowa (IA, Iowa City) and Dyelight
488-conjugated goat anti-mouse IgG F(ab′)2 secondary antibody
(Jackson Immuno Research, West Grove, PA). Images were
obtained using a Zeiss LSM-510 confocal microscope using Zen
software (Carl Zeiss Inc., Thornwood, NY).
Murine Infections and Organ Burden
BALB/c female mice, 6–8 weeks of age, were purchased from
NCI for all sets of animal experiments. Groups of five mice
were used for evaluation of virulence (determining the LD50)
of Francisella strains and groups of six mice were used for
experiments in which bacterial growth in murine organs was
examined. Mice anesthetized with isoflurane (Sigma-Aldrich,
St. Louis, MO) vapor were infected intranasally with 50µl
inocula mixed in PBS and were monitored for up to 26 days
post-infection for the virulence studies. Doses ranging from
101 to 105 CFU were estimated from OD600 readings and
were confirmed by serial dilution and plating of the bacterial
suspension. For determination of bacterial burden in organs,
mice were infected as described above, with mutant strains
at approximately 5- 20-fold lower than the LD50 dose for
each strain. Lungs, livers and spleens were harvested 40 days
post-infection. Organs were homogenized using 50mL tissue
grinders (Thermo Fisher Scientific, Waltham, MA) in 2ml of
1% saponin (ACROS, New Jersey). Organ homogenates were
serially diluted in PBS and plated to enumerate the bacterial load
per organ. All work with F. tularensis Schu S4 was performed
within the Carver College of Medicine Biosafety Level 3 (BSL3)
Core Facility, and all experimental protocols were reviewed for
safety by the BSL3 Oversight Committee of the University of
Iowa Carver College of Medicine. Recombinant DNA work with
F. tularensis Schu S4 was approved by the Institutional Biosafety
Committee.
Results
Identification of F. tularensis Genes Involved in
Capsule and O-antigen Synthesis
A total of nine strains were identified by screening a Tn5
transposon library of F. tularensis Schu S4 with monoclonal
antibodies produced against F. tularensis capsule preparations.
The mutations in three strains, FTT0673p/prsA::Tn5, manB, and
dnaJ, were identified as important in capsule biosynthesis as
the strains displayed reduced binding to the mAb 10E8. In a
second screen, using high affinity mAb 11B7, six strains with
mutations in FTT0846, hemH, waaY, waaL, wbtA, or wzy were
independently identified as having a role in capsule biosynthesis.
The chromosomal locations of the genes were identified by rescue
cloning of the transposon insertion site and sequencing of the
flanking chromosomal DNA (Rasmussen et al., 2014). The sites of
the transposon insertions are shown in Figure 1. The FTT0673,
prsA, FTT0846, and hemH genes that we have identified here
have not been targeted for mutation or identified in previous
genetic screens of Francisella. However, the genes waaY (Weiss
et al., 2007; Lindemann et al., 2011; Case et al., 2013), waaL
(Maier et al., 2007; Weiss et al., 2007; Lindemann et al., 2011),
wbtA (Maier et al., 2007; Su et al., 2007), wzy (Lindemann et al.,
2011), andmanB (Weiss et al., 2007; Lindemann et al., 2011; Case
et al., 2013) genes have been previously identified as important
for Francisella virulence. Although the dnaJ gene has not been
identified previously as important in virulence, its transcription
has been reported to increase during F. tularensis intracellular
growth (Wehrly et al., 2009). Growth rates were determined for
all of the mutant strains and were found to be similar to wild type
Schu S4 (Figure S1).
Characterization of the LPS and Capsule
Structures of F. tularensis Mutants
We have shown previously that mutations in some F. tularensis
genes important for O-antigen and capsule biosynthesis result
in sensitivity to human serum complement (Lindemann
et al., 2011). Serum sensitivity was tested for the F. tularensis
strains with mutations in dnaJ::Tn5, hemH::Tn5, manB::Tn5,
wbtA::Tn5, FTT0846::Tn5, or FTT0673p/prsAp::Tn5 by exposing
them to 50% pooled human serum for 90min at 37◦C. Each
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FIGURE 1 | Chromosomal location of Tn5 insertions. Seven mutant
strains that were disrupted in genes important for capsule production,
were identified from the screened Schu S4 library using the capsule
mAbs 11B7 and 10E8. Rescue cloning was performed and the
plasmids obtained were sent to The University of Iowa School of
Medicine DNA Core for sequencing. A Tn5 primer was used to
sequence the F. tularensis chromosomal DNA flanking the Tn5
transposon insertion. One end of the arrow shows the approximate site
of transposon insertion into the chromosome and the arrow to the left
or right shows the direction of the transposon element.
FIGURE 2 | Comparison of serum sensitivity of mutants to wild
type Schu S4. The serum sensitivity of F. tularensis mutants and
complemented mutants is compared to wild type and is displayed as
fold-change. Data were normalized to wild type. F. tularensis strains
were prepared identically, exposed to pooled human serum for 90min
and then serially diluted.
of the mutants displays some degree of serum sensitivity when
compared to wild type (Figure 2). The fold increase in serum
sensitivity of each F. tularensis mutant strain, compared to
wild type was ∼5 for dnaJ1::Tn5, ∼70 for hemH::Tn5, ∼245
for FTT0673p/prsAp::Tn5, ∼330 for FTT0846, ∼425 for
wbtA::Tn5,∼1.5×103 formanB::Tn5,∼2×103 forwaaL::TrgTn,
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2.4× 104 for wzy::Tn5, and ∼1.6× 107 for waaY ::TrgTn. These
results provided further evidence that the mutated genes
are involved in LPS biosynthesis, capsule biosynthesis, or
biosynthesis of an outer membrane component since these
structures are known to affect serum sensitivity. An effort
was made to complement each of the mutant strains back
to a wild type phenotype but we were only able to restore
functions in the wzy and manB mutants. Complementation
of the wzy or the manB mutation restored serum resistance ∼
500- and ∼8.5 × 103-fold, respectively (Figure 2). Difficulty
in complementing mutants in Francisella has been reported by
several other F. tularensis research groups (Maier et al., 2004;
Zogaj and Klose, 2010; de Bruin et al., 2011).
To more thoroughly characterize the LPS and capsule
produced by each mutant, whole cell lysates were prepared
from each strain and treated with proteinase K. The lysates
were run on an SDS-PAGE gel, transferred to nitrocellulose,
and probed with the anti-O-antigen (FB11) and anti-capsule
antibodies (11B7). The anti-capsule immunoblot revealed that
both the wbtA and wzy mutants lacked detectable capsule
whereas the FTT0846 and manB mutants had altered capsule
species that were of higher molecular weight than wild-type Schu
S4 capsule. Additionally, the altered capsules were less abundant
than that of wild type Schu S4. The dnaJ::Tn5, hemH::Tn5,
or FTT0673p/prsAp::Tn5 mutants appeared to produce capsule
in similar amounts to the parent strain (Figure 3). The anti-
O-antigen immunoblot revealed that the wbtA, FTT0846, and
manB mutants did not show LPS O-antigen laddering, whereas
the wzy mutant produced a truncated LPS associated O-antigen
structure, containing just one or two O-antigen subunits. This
latter phenotype has been previously reported for an LVS wzy
mutant (Kim et al., 2010). The dnaJ, hemH, and FTT0673/prsA
intergenic mutants did not display any detectable difference in
O-antigen laddering in comparison to wild type. Restoration
of capsule production and LPS O-antigen laddering were
observed for both the wzy and manB complemented mutants
(Figure 3).
We have shown previously that mutations in the Francisella
waaY and waaZ genes result in LPS core truncations, in addition
to capsule and O-antigen defects (Rasmussen et al., 2014).
Based upon those observations, whole cell lysates from the
dnaJ::Tn5, hemH::Tn5, manB::Tn5, wbtA::Tn5, FTT0846::Tn5,
and FTT0673p/prsAp::Tn5 mutant strains were stained for the
presence of carbohydrates to determine if the strains carried
defects in the core of the LPS. Mutants in hemH, dnaJ1, wbtA,
andwzy did not appear to have core defects, as the core structures
appeared to be the same as the F. tularensis Schu S4 parent,
whereas the FTT0846 and manB mutants LPS core structures
were either truncated or lacking (Figure 4). If the core structure
is lacking for these mutants it is likely that the band observed is
free lipid A.
FIGURE 4 | Lipopolysaccharide core structures of mutant strains. An
SDS-PAGE gel was loaded with ∼14µg of dried material per mutant per well.
The gel was stained with Emerald green, and is labeled to indicate lipid
A—core—O-antigen (one unit), lipid A—core (no O-antigen subunit), or free
lipid A (indicated by black arrows).
FIGURE 3 | Capsule and LPS O-antigen phenotypes of mutant
strains. Bacteria were grown in MMH broth for ∼24 h and lysed
with Buffer Part A at 65◦C. (A) The anti-capsule mAb (11B7) was
used to detect capsule in whole cell lysates of wild type
F. tularensis, O-antigen mutants, and complemented mutant strains
by immunoblotting. (B) To detect LPS in immunoblots of whole cell
lysates of wild type, mutants, and complemented mutants using the
anti-O-antigen mAb (FB11).
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Determining In Vitro Growth Phenotypes of
Mutants in Human MDMs and Murine BMDMs
Since our previous work has shown that F. tularensis strains
defective in LPS and/or capsule O-antigen biosynthesis have
growth defects in human MDMs (Lindemann et al., 2011), we
examined whether the strains that are the subject of this work
display a similar phenotype in either MDMs or BMDMs. Due to
the serum sensitivity of the mutants, a low percentage of heat-
inactivated pooled human serum was used in the tissue culture
media of the MDMs to prevent serum-induced killing of the
bacteria. MDMs were infected at an MOI of 100:1 with wild
type Schu S4, wbtA::Tn5, wzy::Tn5, manB::Tn5, FTT0846::Tn5,
hemH::Tn5, FTT0673p/prsAp::Tn5, dnaJ::Tn5, and waaY ::TrgTn
as a negative control. Due to the number of strains being tested,
we separated the strains into two separate groups (Group 1—
wild type, wbtA::Tn5, wzy::Tn5 and manB::Tn5 and Group 2—
wild type, FTT0846::Tn5, hemH::Tn5, FTT0673p/prsAp::Tn5 and
dnaJ::Tn5) to perform humanMDM infection and growth assays.
Time points were taken at 1, 16, and 24 h post-infection to
determine how many bacteria were present in the MDM host
cells at each time point so that growth within the cells could be
calculated. In contrast to the phenotype ofwaaY,waaZ, andwaaL
mutants, which exhibit increased uptake into MDMs (although
overall growth of these strains was comparable to Schu S4 until
16 h) (Lindemann et al., 2011), the seven new mutants tested
did not differ significantly in uptake or in growth rate up to
16 h post-infection (Figure 5). However, at the 24 h time point
it was clear that strains with mutations in wbtA, wzy, manB,
and FTT0846 did not increase in number compared to the 16 h
time point while wild type strain continued to replicate rapidly.
This is a similar phenotype to that observed with the waaL,
waaY, and waaZ mutants, as growth was limited from 16 to
48 h post-infection (Lindemann et al., 2011). Not surprisingly,
the hemH, dnaJ, and the intergenic FTT0673/prsA mutants did
not differ considerably from wild type for growth in MDMs,
since the LPS, capsule and core sugar properties of these strains
were not significantly different from the parent Schu S4 (Figure 5
and Figure S2). Since the hemH, dnaJ, and the intergenic
FTT0673/prsA mutants did not have significant differences in
LPS, capsule or core sugar properties, or growth in MDMs, we
focused our efforts on characterizing the other mutants in more
detail.
In addition to the intracellular MDM growth assay, mutant
strains were also analyzed by confocal microscopy. Macrophages
were infected at an MOI of 100:1 with wild type Schu S4
and mutant strains. The confocal microscopy data suggest that
wbtA::Tn5, wzy::Tn5,manB::Tn5 and FTT0846::Tn5 strains were
phagocytosed to the same extent as wild type, and did not
colocalize with the Lamp-1 lysosomal marker, despite diminished
intracellular growth at later stages of infection (Figure 6).
Similar to the human MDM experiments, the BMDMs were
infected at an MOI of 100:1, using heat-inactivated serum, and
growth data was collected 1, 16, and 24 h post-infection. The data
revealed that the FTT0846::Tn5, manB::Tn5, and the negative
control, waaY ::TrgTn appeared to infect BMDMs slightly better
than wild type; whereas, wbtA::Tn5 and wzy::Tn5 appeared to
have similar entry levels into murine BMDMs. Regardless of
uptake efficiency, none of the F. tularensis mutants was able
FIGURE 5 | Intracellular growth of wbtA, wzy, manB, 0846, hemH,
dnaJ, waaY, and 0673/prsA intergenic mutants in MDMs. Triplicate
wells containing human macrophages were infected for 1 h with unopsonized
Schu S4 or mutant bacteria, washed to remove extracellular organisms, and
then lysed with 1% saponin at 1, 16, and 24 h post infection to enumerate
viable bacteria. Data presented show fold growth change from 1–16 h
post-infection to 1–24 h post-infection. Data are from one experiment
representative of three different experiments.
Frontiers in Microbiology | www.frontiersin.org 7 May 2015 | Volume 6 | Article 338
Rasmussen et al. Characterization of F. tularensis LPS/capsule mutants
FIGURE 6 | Microscopy of infected MDMs with wbtA, wzy, manB, and
FTT0846 mutants. Confocal images show Lamp-1 in green and bacteria in
red. MDMs were infected with (A) wild type Schu S4 as the positive control,
waaY ::TrgTn as a negative control, and with (B) wbtA::Tn5, wzy::Tn5,
manB::Tn5, or FTT0846::Tn5 strains at an MOI of 100:1. Samples were fixed
and processed at 1 and 12 h post infection.
to replicate within the BMDMs to any significant extent over
the course of the 24 h infection (Figure 7 and Figure S3). These
data suggest that the internalized organisms were viable but were
unable to grow in murine macrophages.
Determination of Virulence and Organ
Dissemination in Murine Infections
In an effort to extend these observations and test the effects of the
mutations on mouse virulence, mice were infected intranasally
with F. tularensis Schu S4 (23 CFU), or with F. tularensismutant
strains, dnaJ::Tn5, hemH::Tn5,manB::Tn5,wbtA::Tn5,wzy::Tn5,
FTT0673p/prsAp::Tn5, and FTT0846::Tn5 with doses ranging
from 101 to 105 CFU. As was observed before during murine
infections with the waaY and waaL mutants (Rasmussen et al.,
2014), mice infected withmanB, wbtA, wzy, or FTT0846mutants
displayed piloerection (ruﬄed fur) and lethargy as early as 24 h
post-infection regardless of dose. These observations are in
contrast to what was observed with mice infected with wild type,
dnaJ::Tn5, hemH::Tn5, or FTT0673p/prsAp::Tn5. Those mice did
not appear sick until 72–96 h post-infection. Mice infected with
the intergenic FTT0673/prsA, dnaJ, or hemH mutants did not
survive any of the doses tested (Table 1), indicating that these
strains retain virulence similar to parent F. tularensis Schu S4,
as mutant-infected mice died on a similar time frame as wild
type. Using the Muench and Reed calculation method (Reed and
Muench, 1938), we determined the i.n. LD50 values to be 5× 10
3
for manB::Tn5, 2.6× 102 for wbtA::Tn5, 1.2× 104 for wzy::Tn5,
and 1.5× 103 CFU for FTT0846::Tn5 (Table 1 and Figure S4).
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FIGURE 7 | Intracellular growth of FTT0846, wbtA, wzy, and manB
mutants in BMDMs. Murine macrophages were infected for 1 h with
unopsonized Schu S4 or mutant bacteria, washed to remove
extracellular organisms, and then lysed with 0.5% saponin at 1, 16, and
24 h post infection to enumerate viable bacteria. Data presented shows
fold growth change from 1–16 h post infection to 1–24 h post infection.
Data are from one experiment that is representative of three
experiments.
Discussion
In this work, we identify F. tularensis strains that are defective
in capsule and/or LPS biosynthesis by using ELISA to screen
a F. tularensis Schu S4 transposon mutant library (7500
individual mutants) (Rasmussen et al., 2014). We identified
insertions in six different genes [waaY (2 unique insertions),
waaL (3 unique insertions), wzy, wbtA, hemH, and FTT0846]
that we subsequently demonstrated were important in capsule
biosynthesis (Rasmussen et al., 2014). The waaY and waaL
genes were also identified previously in our lab from a TraSH
screen in humanMDMs (Lindemann et al., 2011). Re-identifying
mutants in the waaL and waaY genes provided a strong
level of confidence that the other mutant strains identified by
ELISA were altered in capsule and/or LPS biogenesis. Since
our group has previously identified and characterized the roles
of waaY and waaL in capsule and LPS biosynthesis, we have
used these strains as controls for the characterization of the
new mutants. Consistent with involvement in capsule and LPS
biosynthesis, we found that mutation of each of these genes
rendered the strains more sensitive to human pooled serum
(from 5-fold to 2.4 × 104-fold) than the parent F. tularensis
Schu S4. These results are similar to what is observed in other
organisms when capsule and/or LPS genes are mutated (Cryz
et al., 1984; Rietschel, 1984; Stawski et al., 1990; Dasgupta
et al., 1994). Examination of the hemH::Tn5, dnaJ::Tn5, and
FTT0673p/prsAp::Tn5 strains revealed that they did not have
defects in capsule or LPS that could detected by the assays
used, nor did these three mutant strains display attenuated
macrophage growth defects or in vivo virulence defects. While
these strains were observed to have varying levels of sensitivity
to human serum, the amount of serum present in the pooled
human serum sensitivity assay is significantly more than in
the in vitro cell infection assay. This likely explains why no
intramacrophage growth defect was observed with these three
strains. Although it is not clear why hemH::Tn5, dnaJ::Tn5, and
FTT0673p/prsAp::Tn5 were identified from the ELISA screen,
it may have been that the growth conditions employed for
the initial ELISA screen maximized differences in expression
of capsule and/or LPS production between these strains and
the wild type positive control. Besides identifying these three
mutant strains of low interest, the ELISA screens identified
six mutant strains of high interest that are altered in capsule
and/or LPS production, of which four (wzy::Tn5, wbtA:Tn5,
manB::Tn5, and FTT0846::Tn5) are characterized further here.
Complementation of the defects in these strains was attempted
several times with different vector constructs, including with a
vector driving expression of the genes with the Pgro promoter.
Thus, we conclude that for the FTT0846::Tn5 and wbtA::Tn5
mutant strains that the phenotypes observed are either due to
disruption of the gene in which the transposon is inserted or to
downstream polar effects.
In examining the annotated functions of wzy, wbtA, manB
and FTT0846, it is unclear how the annotated function
of the FTT0846 gene product is relevant to LPS and/or
capsule biosynthesis. FTT0846 is predicted to encode a
deoxyribodipyrimidine photolyase, a class of proteins that are
involved in sensing blue light to repair DNA damage. However, it
has been postulated that bacterial photolyases can be involved in
virulence by regulating the transcription of genes either directly
or indirectly (Gaidenko et al., 2006; Purcell et al., 2007; Swartz
et al., 2007; Purcell and Crosson, 2008; Cahoon et al., 2011). It is
possible that protein produced by FTT0846 is involved in some
way in the regulation of LPS core assembly or synthesis, due to
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TABLE 1 | Murine virulence studies and experimentally determined
intranasal LD50 values for F. tularensis Schu S4 and capsule and/or LPS
mutants.
Strain Infection Survival Mean Calc
dose (CFU) ratio TTD LD50 (CFU)
INTRANASAL
WT 23 0/5 5 <23
dnaJ::Tn5 1.0× 102 0/5 4.8 <100
dnaJ::Tn5 1.0× 1.03 0/5 4.8
dnaJ::Tn5 1.0× 104 0/5 4.4
dnaJ::Tn5 1.0× 105 0/5 4
hemH::Tn5 1.1× 102 0/5 6 <110
hemH::Tn5 1.1× 103 0/5 5
hemH::Tn5 1.1× 104 0/5 4.2
hemH::Tn5 1.1× 105 0/5 4
manB::Tn5 1.0× 102 5/5 >27 5× 103
manB::Tn5 1.0× 103 5/5 >27
manB::Tn5 1.0× 104 0/5 7.6
manB::Tn5 1.0× 105 0/5 6.6
wbtA::Tn5 1.8× 101 4/4 >27 2.6× 102
wbtA::Tn5 1.8× 102 3/5 >27
wbtA::Tn5 1.8× 103 0/5 17.6
wbtA::Tn5 1.8× 104 0/5 7.6
wzy::Tn5 1.2× 102 5/5 >27 1.2× 104
wzy::Tn5 1.2× 103 4/5 8, >27
wzy::Tn5 1.2× 104 3/5 8, >27
wzy::Tn5 1.2× 105 0/5 5.8
FTT0673plprsAp::Tn5 1.4× 102 0/5 5.8 <140
FTT0673plprsAp::Tn5 1.4× 103 0/5 5
FTT0673p/prsAp::Tn5 1.4× 104 0/5 4.8
FTT0673plprsAp::Tn5 1.4× 105 0/5 4.2
FTTOB46::Tn5 6.5× 101 5/5 >27 1.5× 103
FTTOB46::Tn5 6.5× 102 4/5 25, >27
FTTOB46::Tn5 6.5× 103 0/5 17
FTTOB46::Tn5 6.5× 104 0/5 12
the degree of serum sensitivity, a MDM growth defect, and the
truncated core observed in the FTT0846 mutant. Future work
will be aimed at exploring these possibilities in detail.
For the three other mutants identified from the screens,
wbtA::Tn5,wzy::Tn5, andmanB::Tn5, there are clear connections
to capsule and LPS synthesis. WbtA is a dTDP-glucose 4,6-
dehydratase and has been shown in LVS (Raynaud et al., 2007;
Sebastian et al., 2007) and other pathogenic organisms such
as Pseudomonas aeruginosa, Bordetella pertussis, and Yersinia
enterocolitica to be essential for complete LPS biosynthesis
(Creuzenet and Lam, 2001). Specifically, WbtA orthologs are
involved in the formation of 6-deoxy sugars (Creuzenet et al.,
2000; Creuzenet and Lam, 2001), and the first sugar in the
tetrasaccharide repeat of F. tularensis is a 6-deoxy sugar, QuiNAc
(Vinogradov et al., 2002). We have presented wbtA mutant data
that is consistent with the presumed function of this gene in F.
tularensis, as the serum sensitivity of the mutant is increased and
a complete LPS core is present, but capsule and LPS-associatedO-
antigens are not produced as we could not detect these structures
in our assays. Interestingly, the glycosylated proteins that we have
reported to be present in a waaY mutant strain (Jones et al.,
2014), are not present in the wbtA mutant, providing further
support for the idea that the wbtA gene product is important for
producing complete O-antigen subunits (data not shown).
TheWzy protein is annotated as anO-antigen polymerase and
this function was confirmed by Kim et al. (2010) in LVS. The LVS
wzy mutant has normal LPS core, but has only one O-antigen
tetrasaccharide repeat attached to core (Kim et al., 2010). From
our data, the Schu S4 wzymutant was observed to have a similar
phenotype (intact core with only one O-antigen tetrasaccharide
repeat). In addition, we observed that this strain lackedO-antigen
reactive capsule and displayed an increase in sensitivity to serum.
ManB is a phosphomannose mutase that has been shown
in F. novicida to be important for LPS core production (Lai
et al., 2010). The Schu S4 manB::Tn5 has a phenotype similar
to the F. novicida manB mutant. Experiments to visualize LPS
laddering in the Schu S4 manB mutant revealed that it was
absent. Surprisingly, we observed that both the FTT0846 and
manB mutants produced higher than normal molecular weight
capsules albeit in reduced amounts. An unanticipated result from
this work has been that mutants with defects in the F. tularensis
core sugar assembly pathway do not produce normal LPS O-
antigen laddering, yet they still produce capsule which appears
larger in size than its wild-type counterpart. An exception to
this observation is the F. tularensis waaY ::TrgTn mutant strain
that does not produce LPS O-antigen laddering or capsule.
However, it should be noted that this strain has a polar insertion
which also disrupts the downstream gene, waaZ. A goal of the
work by our group is to understand this phenomenon in more
detail.
When the manB, wzy, wbtA and FTT0846 mutants were used
to infectMDMs, no observable differences in intracellular growth
were detected at 1 h post–infection or at 16 h post–infection
compared to the parent F. tularensis Schu S4. However, by
24 h post–infection there were substantial differences in growth
between the mutant strains and the wild type strain, indicating
that replication of the mutants in MDMs at later stages of
infection is impaired. These phenotypes are similar to those
we reported previously for the F. tularensis Schu S4 waaY,
waaZ, and waaY O-antigen and capsule mutants (Lindemann
et al., 2011). The mutants are even less able to grow within
murine macrophages as the manB, wzy, wbtA, and FTT0846
mutants displayed almost no growth in bone marrow derived
macrophages during the 24 h infection experiment.
In addition to in vitro experiments, virulence studies were
performed by intranasally infecting mice with the manB, wzy,
wbtA or FTT0846mutants, and their respective LD50 values were
calculated to be 5.0 × 103-fold, 1.2 × 104-fold, 260-fold, and
1.5 × 103-fold more than the previously published wild type
theoretical LD50 of ∼1 CFU (Kim et al., 2012). Mice that were
infected with manB::Tn5, wbtA::Tn5, wzy::Tn5 or FTT0846::Tn5
displayed ruﬄed fur (piloerection) within 24–48 h post-infection,
suggestive of a gross inflammatory response, similar to what
we observed for mice infected with the waaY ::TrgTn or
waaL::TrgTn strains (Rasmussen et al., 2014). These data are
consistent with the in vitro cell growth results in human MDMs
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and murine BMDMs, in that these mutations impair intracellular
growth when compared to Schu S4 over 24 h. In contrast,
the hemH::Tn5, dnaJ::Tn5, and FTT0673p/prsAp::Tn5 strains
did not have a growth phenotype in macrophages, did not
elicit gross inflammatory responses in mice, and did not show
an increase in their LD50 values for mice compared to wild
type.
As mentioned previously, work has been done with
F. tularensis LVS wzy and wbtA mutants. Although our
data are in agreement with the O-antigen defects, serum
sensitivity, and intramacrophage growth defect reported by
other groups with LVS mutants (Raynaud et al., 2007; Sebastian
et al., 2007; Thomas et al., 2007; Kim et al., 2010), we observed
significantly less diminution of virulence in our i.n. infection
experiments using the Schu S4 mutant strains. Sebastian et al.
(2007) and Kim et al. (2012) showed that mice infected with
either a LVS wbtA or wzy mutant survived a 107 CFU i.n.
infection, which is a 20,000-fold increase in the LVS LD50.
However, we observed 26-fold and 1200-fold increase in the
LD50 values, respectively, for the Schu S4 wbtA and Schu S4 wzy
mutants intranasally infected into mice. These data highlight the
importance of considering strain background in understanding
the role and contribution to virulence of different Francisella
factors.
In summary, we present further evidence that the LPS and
capsule structures of F. tularensis are essential components
of its virulence strategy. Mutations in wzy, wbtA, manB, and
FTT0846 affect capsule production, or LPS core and O-antigen
structures (Figure 8). In general, mutants with defects in LPS
or capsule are sensitive to serum, do not show robust growth
after 16 h within human macrophages nor do they grow in
murine macrophages, and are attenuated in a murine infection
FIGURE 8 | Diagram depicting the activities of the F. tularensis
WaaY, WaaZ, WaaL, ManB, 0846, Wzy, and WbtA proteins in LPS
biosynthesis. LPS is synthesized as two separate components, which are
(1) lipid A-core sugars and (2) polymers of O-antigen subunits. O-antigen
sugars are synthesized in part by WbtA in the cytoplasm and assembled
onto a lipid carrier, the undecaprenol pyrophosphate that is associated with
WbaP or PNPT, polyisoprenyl-phosphate hexose-1-phosphate transferase
and N-acetylhexosamine-1-phosphate transferase, respectively. The Wzx
protein flips the charged lipid carrier, with the assembled O-antigen unit,
through the inner membrane from the cytoplasm to the periplasmic space.
Repeating O-antigen subunits are polymerized on the lipid carrier by the
Wzy protein. The lipid A portion of LPS is synthesized by a number of Lpt
and Lpx proteins at the inner leaflet of the inner bacterial membrane. WaaY,
WaaZ, and ManB proteins modify or transfer core sugars to the lipid A
molecule as they help assemble the core structure of LPS. ValA and LptB
transports the lipid A-core sugars to the outer leaflet of the inner
membrane where O-antigen subunits are added by the O-antigen ligase,
WaaL, and the mature molecule is chaperoned to the outer membrane by
LptA and LptD/RlpB (Kim et al., 2010). Possibly the FTT0846 protein is
involved in regulation of core sugar genes. F. tularensis mutants that are
disrupted in FTT0846 or manB production are depicted with truncated
cores whereas the lipid-core sugar structure of the wbtA mutant has a
complete core, but no O-antigen. The wzy mutant has a complete core
and a single O-antigen tetrasaccharide unit.
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FIGURE 9 | Phenotypes of capsule and/or O-antigen mutants.
Properties of the F. tularensis mutants include the presence or absence of
capsule, O-antigen, intact core, or O-antigen associated glycosylated
proteins (Jones et al., 2014). FTT0846::Tn5, manB::Tn5, and waaZ::TrgTn
are shown with a capsule structure that is higher in molecular weight but
reduced in concentration when compared to wild type.
model. In total, our research group has identified seven mutant
strains that display varying differences in LPS core structure,
LPS-associated O-antigen, capsule, and O-antigen glycosylated
proteins in comparison to Schu S4 (Figure 9). These strains are
of interest as they grow poorly in macrophages or mouse in
an infection model which demonstrates that they are attenuated
for virulence. We believe that our data demonstrate that these
mutant strains are being detected by the host, which may be
a critical first step toward development of a vaccine to an
immunologically invisible pathogen. Future studies will focus
on what pathway(s) are activated and the degree to which
each mutant stimulates a response. The loss of capsule/O-
antigen structures allows some level of host recognition of the
pathogen, but clearly does not render the strains avirulent.
As such, these strains may be reasonable models for genetic
dissection of other components of Francisella virulence. In
addition, we believe that these strains may be an appropriate
place to begin development of a viable, defined vaccine for
tularemia.
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Figure S1 | Growth curves of F. tularensis Schu S4 and each of the
mutants. Every 2 h samples were taken from each of the cultures and the OD600
was determined.
Figure S2 | Intracellular growth of wbtA, wzy, manB, 0846, hemH, dnaJ,
waaY, and 0673/prsA intergenic mutants in MDMs. Triplicate wells containing
human macrophages were infected for 1 h with unopsonized Schu S4 or mutant
bacteria, washed to remove extracellular organisms, and then lysed with 1%
saponin at 1, 16, and 24 h post infection to enumerate viable bacteria. Data
presented show the average number of bacteria recovered for each strain at 1,
16, and 24 h post-infection. Data are from one experiment representative of three
different experiments. (A) Data for the wild type, manB::Tn5, wzy::Tn5, wbtA::Tn5
F. tularensis strains. (B) Data for the wild type, FTT0846::Tn5, hemH::Tn5,
FTT0673p/prsAp::Tn5, dnaJ::Tn5, waaY ::Tn5 F. tularensis strains.
Figure S3 | Intracellular growth of FTT0846, wbtA, wzy, and manB mutants
in BMDMs. Murine macrophages were infected for 1 h with unopsonized Schu
S4 or mutant bacteria, washed to remove extracellular organisms, and then lysed
with 0.5% saponin at 1, 16, and 24 h post-infection to enumerate viable bacteria.
Data presented shows the average number of bacteria recovered for each strain
at 1, 16, and 24 h post-infection. Data are from one experiment that is
representative of three experiments.
Figure S4 | Survival curves of BALB/c mice infected with F. tularensis
Schu S4 wild type or mutant strains carrying transposon insertions in
dnaJ, hemH, manB, wzy, wbtA, FTT0846 and between FTT0673 and the
prsA gene. Mice were infected with 23 cfu of F. tularensis Schu S4 as a positive
control for virulence. Four groups of mice were infected for each of the indicated
F. tularensis mutant strain at mice that were alive each day from each group was
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recorded and is shown on the graph. Mice infected with strains with mutations
that did not significantly alter virulence were typically dead at day 5 or day 6. Mice
infected with attenuated strains were followed up to 40 days post-infection
depending upon signs of illness such as piloerection, hunching and lethargy.
Some infected groups of mice became ill at significantly delayed time points and
those groups of mice were followed for extended periods of time. Ultimately all
mice were sacrificed according to protocol and disposed of in accordance with
BSL-3 regulations.
References
Allen, L. A., and Aderem, A. (1996). Molecular definition of distinct cytoskeletal
structures involved in complement- and Fc receptor-mediated phagocytosis in
macrophages. J. Exp. Med. 184, 627–637. doi: 10.1084/jem.184.2.627
Apicella, M. A., Post, D. M., Fowler, A. C., Jones, B. D., Rasmussen, J. A., Hunt, J.
R., et al. (2010). Identification, characterization and immunogenicity of an O-
antigen capsular polysaccharide of Francisella tularensis. PLoS ONE 5:e11060.
doi: 10.1371/journal.pone.0011060
Barker, J. R., and Klose, K. E. (2007). Molecular and genetic basis of
pathogenesis in Francisella tularensis. Ann. N.Y. Acad. Sci. 1105, 138–159. doi:
10.1196/annals.1409.010
Buchan, B. W., McLendon, M. K., and Jones, B. D. (2008). Identification
of differentially regulated Francisella tularensis genes by use of a newly
developed Tn5-based transposon delivery system. Appl. Environ. Microbiol. 74,
2637–2645. doi: 10.1128/AEM.02882-07
Cahoon, L. A., Stohl, E. A., and Seifert, H. S. (2011). The Neisseria gonorrhoeae
photolyase orthologue phrB is required for proper DNA supercoiling but
does not function in photo-reactivation. Mol. Microbiol. 79, 729–742. doi:
10.1111/j.1365-2958.2010.07481.x
Carvalho, C. L., Lopes de Carvalho, I., Ze-Ze, L., Nuncio, M. S., and Duarte, E. L.
(2014). Tularaemia: a challenging zoonosis. Comp. Immunol. Microbiol. Infect.
Dis. 37, 85–96. doi: 10.1016/j.cimid.2014.01.002
Case, E. D., Chong, A., Wehrly, T. D., Hansen, B., Child, R., Hwang, S., et al.
(2013). The Francisella O-antigen mediates survival in the macrophage cytosol
via autophagy avoidance. Cell. Microbiol.
Center for Disease Control and Prevention. (2013). Tularemia - United States,
2001-2010. MMWRMorb. Mortal. Wkly. Rep. 62, 963–966.
Clay, C. D., Soni, S., Gunn, J. S., and Schlesinger, L. S. (2008). Evasion of
complement-mediated lysis and complement C3 deposition are regulated
by Francisella tularensis lipopolysaccharide O antigen. J. Immunol. 181,
5568–5578. doi: 10.4049/jimmunol.181.8.5568
Comstock, L. E., and Kasper, D. L. (2006). Bacterial glycans: key
mediators of diverse host immune responses. Cell 126, 847–850. doi:
10.1016/j.cell.2006.08.021
Creuzenet, C., and Lam, J. S. (2001). Topological and functional characterization
of WbpM, an inner membrane UDP-GlcNAc C6 dehydratase essential for
lipopolysaccharide biosynthesis in Pseudomonas aeruginosa.Mol.Microbiol. 41,
1295–1310. doi: 10.1046/j.1365-2958.2001.02589.x
Creuzenet, C., Schur, M. J., Li, J., Wakarchuk, W. W., and Lam, J. S.
(2000). FlaA1, a new bifunctional UDP-GlcNAc C6 Dehydratase/ C4
reductase from Helicobacter pylori. J. Biol. Chem. 275, 34873–34880. doi:
10.1074/jbc.M006369200
Cryz, S. J. Jr, Pitt, T. L., Furer, E., and Germanier, R. (1984). Role of
lipopolysaccharide in virulence of Pseudomonas aeruginosa. Infect. Immun. 44,
508–513.
Dasgupta, T., de Kievit, T. R., Masoud, H., Altman, E., Richards, J. C., Sadovskaya,
I., et al. (1994). Characterization of lipopolysaccharide-deficient mutants of
Pseudomonas aeruginosa derived from serotypes O3, O5, and O6. Infect.
Immun. 62, 809–817.
de Bruin, O. M., Duplantis, B. N., Ludu, J. S., Hare, R. F., Nix, E. B., Schmerk, C. L.,
et al. (2011). The biochemical properties of the Francisella pathogenicity island
(FPI)-encoded proteins IglA, IglB, IglC, PdpB and DotU suggest roles in type
VI secretion.Microbiology 157, 3483–3491. doi: 10.1099/mic.0.052308-0
Gaidenko, T. A., Kim, T. J., Weigel, A. L., Brody, M. S., and Price, C. W. (2006).
The blue-light receptor YtvA acts in the environmental stress signaling pathway
of Bacillus subtilis. J. Bacteriol. 188, 6387–6395. doi: 10.1128/JB.00691-06
Ho, T. D., andWaldor, M. K. (2007). Enterohemorrhagic Escherichia coliO157:H7
gal mutants are sensitive to bacteriophage P1 and defective in intestinal
colonization. Infect. Immun. 75, 1661–1666. doi: 10.1128/IAI.01342-06
Iredell, J. R., Stroeher, U. H., Ward, H. M., and Manning, P. A. (1998).
Lipopolysaccharide O-antigen expression and the effect of its absence on
virulence in rfb mutants ofVibrio choleraeO1. FEMS Immunol. Med. Microbiol.
20, 45–54. doi: 10.1016/S0928-8244(97)00106-5
Jones, B. D., Faron, M., Rasmussen, J. A., and Fletcher, J. R. (2014). Uncovering the
components of the Francisella tularensis virulence stealth strategy. Front. Cell.
Infect. Microbiol. 4:32. doi: 10.3389/fcimb.2014.00032
Kim, T. H., Pinkham, J. T., Heninger, S. J., Chalabaev, S., and Kasper, D. L. (2012).
Genetic modification of the O-polysaccharide of Francisella tularensis results
in an avirulent live attenuated vaccine. J. Infect. Dis. 205, 1056–1065. doi:
10.1093/infdis/jir620
Kim, T. H., Sebastian, S., Pinkham, J. T., Ross, R. A., Blalock, L. T., and Kasper, D.
L. (2010). Characterization of the O-antigen polymerase (Wzy) of Francisella
tularensis. J. Biol. Chem. 285, 27839–27849. doi: 10.1074/jbc.M110.143859
Lai, X. H., Shirley, R. L., Crosa, L., Kanistanon, D., Tempel, R., Ernst, R. K.,
et al. (2010). Mutations of Francisella novicida that alter the mechanism
of its phagocytosis by murine macrophages. PLoS ONE 5:e11857. doi:
10.1371/journal.pone.0011857
Li, J., Ryder, C., Mandal, M., Ahmed, F., Azadi, P., Snyder, D. S., et al.
(2007). Attenuation and protective efficacy of an O-antigen-deficient
mutant of Francisella tularensis LVS. Microbiology 153, 3141–3153. doi:
10.1099/mic.0.2007/006460-0
Lindemann, S. R., Peng, K., Long, M. E., Hunt, J. R., Apicella, M. A., Monack,
D. M., et al. (2011). Francisella tularensis Schu S4 O-antigen and capsule
biosynthesis gene mutants induce early cell death in human macrophages.
Infect. Immun. 79, 581–594. doi: 10.1128/IAI.00863-10
Maier, T. M., Casey, M. S., Becker, R. H., Dorsey, C. W., Glass, E. M.,
Maltsev, N., et al. (2007). Identification of Francisella tularensis Himar1-based
transposon mutants defective for replication in macrophages. Infect. Immun.
75, 5376–5389. doi: 10.1128/IAI.00238-07
Maier, T. M., Havig, A., Casey, M., Nano, F. E., Frank, D. W., and Zahrt,
T. C. (2004). Construction and characterization of a highly efficient
Francisella shuttle plasmid. Appl. Environ. Microbiol. 70, 7511–7519. doi:
10.1128/AEM.70.12.7511-7519.2004
McLendon, M. K., Apicella, M. A., and Allen, L. A. (2006). Francisella
tularensis: taxonomy, genetics, and Immunopathogenesis of a
potential agent of biowarfare. Annu. Rev. Microbiol. 60, 167–185. doi:
10.1146/annurev.micro.60.080805.142126
Oyston, P. C. (2008). Francisella tularensis: unravelling the secrets
of an intracellular pathogen. J. Med. Microbiol. 57, 921–930. doi:
10.1099/jmm.0.2008/000653-0
Oyston, P. C., Sjostedt, A., and Titball, R. W. (2004). Tularaemia: bioterrorism
defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2,
967–978. doi: 10.1038/nrmicro1045
Post, D. M., Yu, L., Krasity, B. C., Choudhury, B., Mandel, M. J., Brennan,
C. A., et al. (2012). O-antigen and core carbohydrate of Vibrio fischeri
lipopolysaccharide: composition and analysis of their role in Euprymna
scolopes light organ colonization. J. Biol. Chem. 287, 8515–8530. doi:
10.1074/jbc.M111.324012
Prior, J. L., Prior, R. G., Hitchen, P. G., Diaper, H., Griffin, K. F., Morris, H. R., et al.
(2003). Characterization of the O antigen gene cluster and structural analysis of
the O antigen of Francisella tularensis subsp. tularensis. J. Med. Microbiol. 52,
845–851. doi: 10.1099/jmm.0.05184-0
Purcell, E. B., and Crosson, S. (2008). Photoregulation in prokaryotes. Curr. Opin.
Microbiol. 11, 168–178. doi: 10.1016/j.mib.2008.02.014
Purcell, E. B., Siegal-Gaskins, D., Rawling, D. C., Fiebig, A., and Crosson, S. (2007).
A photosensory two-component system regulates bacterial cell attachment.
Proc. Natl. Acad. Sci. U.S.A. 104, 18241–18246. doi: 10.1073/pnas.0705887104
Rasmussen, J. A., Post, D. M., Gibson, B. W., Lindemann, S. R., Apicella, M. A.,
Meyerholz, D. K., et al. (2014). Francisella tularensis Schu S4 LPS core sugar
Frontiers in Microbiology | www.frontiersin.org 13 May 2015 | Volume 6 | Article 338
Rasmussen et al. Characterization of F. tularensis LPS/capsule mutants
and O-antigen mutants are attenuated in a mouse model of Tularemia. Infect.
Immun. 82, 1523–1539. doi: 10.1128/IAI.01640-13
Raynaud, C., Meibom, K. L., Lety, M. A., Dubail, I., Candela, T., Frapy, E., et al.
(2007). Role of the wbt locus of Francisella tularensis in lipopolysaccharide
O-antigen biogenesis and pathogenicity. Infect. Immun. 75, 536–541. doi:
10.1128/IAI.01429-06
Reed, L. J., and Muench, H. (1938). A simple method of estimating fifty per cent
endpoints. Am. J. Epidemiol. 27, 493–497.
Rietschel, E. T. (1984). Chemistry of Endotoxin. New York, NY: Elsevier; Sole
distributor for the USA and Canada, Elsevier Science Pub. Co., Amsterdam;
New York.
Sandstrom, G., Lofgren, S., and Tarnvik, A. (1988). A capsule-deficient mutant
of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum
but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect.
Immun. 56, 1194–1202.
Saslaw, S., Eigelsbach, H. T., Prior, J. A., Wilson, H. E., and Carhart, S. (1961).
Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107,
702–714. doi: 10.1001/archinte.1961.03620050068007
Schulert, G. S., and Allen, L. A. (2006). Differential infection of mononuclear
phagocytes by Francisella tularensis: role of the macrophage mannose receptor.
J. Leukoc. Biol. 80, 563–571. doi: 10.1189/jlb.0306219
Sebastian, S., Dillon, S. T., Lynch, J. G., Blalock, L. T., Balon, E., Lee, K. T., et al.
(2007). A definedO-antigen polysaccharide mutant of Francisella tularensis live
vaccine strain has attenuated virulence while retaining its protective capacity.
Infect. Immun. 75, 2591–2602. doi: 10.1128/IAI.01789-06
Sheng, H., Lim, J. Y., Watkins, M. K., Minnich, S. A., and Hovde, C. J. (2008).
Characterization of an Escherichia coli O157:H7 O-antigen deletion mutant
and effect of the deletion on bacterial persistence in the mouse intestine and
colonization at the bovine terminal rectal mucosa. Appl. Environ. Microbiol. 74,
5015–5022. doi: 10.1128/AEM.00743-08
Sjostedt, A. (2007). Tularemia: history, epidemiology, pathogen physiology,
and clinical manifestations. Ann. N.Y. Acad. Sci. 1105, 1–29. doi:
10.1196/annals.1409.009
Stawski, G., Nielsen, L., Orskov, F., and Orskov, I. (1990). Serum sensitivity of a
diversity of Escherichia coli antigenic reference strains. Correlation with an LPS
variation phenomenon. APMIS 98, 828–838.
Su, J., Yang, J., Zhao, D., Kawula, T. H., Banas, J. A., and Zhang, J. R. (2007).
Genome-wide identification of Francisella tularensis virulence determinants.
Infect. Immun. 75, 3089–3101. doi: 10.1128/IAI.01865-06
Swartz, T. E., Tseng, T. S., Frederickson, M. A., Paris, G., Comerci, D. J.,
Rajashekara, G., et al. (2007). Blue-light-activated histidine kinases:
two-component sensors in bacteria. Science 317, 1090–1093. doi:
10.1126/science.1144306
Tarnvik, A., and Berglund, L. (2003). Tularaemia. Eur. Respir. J. 21, 361–373. doi:
10.1183/09031936.03.00088903
Thomas, R. M., Titball, R. W., Oyston, P. C., Griffin, K., Waters, E., Hitchen, P.
G., et al. (2007). The immunologically distinct O antigens from Francisella
tularensis subspecies tularensis and Francisella novicida are both virulence
determinants and protective antigens. Infect. Immun. 75, 371–378. doi:
10.1128/IAI.01241-06
Vinogradov, E., Perry, M. B., and Conlan, J. W. (2002). Structural analysis of
Francisella tularensis lipopolysaccharide. Eur. J. Biochem. 269, 6112–6118. doi:
10.1046/j.1432-1033.2002.03321.x
Wang, Q., Shi, X., Leymarie, N., Madico, G., Sharon, J., Costello, C. E., et al.
(2011). A typical preparation of Francisella tularensis O-antigen yields a
mixture of three types of saccharides. Biochemistry 50, 10941–10950. doi:
10.1021/bi201450v
Wehrly, T. D., Chong, A., Virtaneva, K., Sturdevant, D. E., Child, R., Edwards,
J. A., et al. (2009). Intracellular biology and virulence determinants
of Francisella tularensis revealed by transcriptional profiling inside
macrophages. Cell. Microbiol. 11, 1128–1150. doi: 10.1111/j.1462-5822.2009.
01316.x
Weiss, D. S., Brotcke, A., Henry, T., Margolis, J. J., Chan, K., and Monack,
D. M. (2007). In vivo negative selection screen identifies genes required
for Francisella virulence. Proc. Natl. Acad. Sci. U.S.A. 104, 6037–6042. doi:
10.1073/pnas.0609675104
Whitfield, C. (2006). Biosynthesis and assembly of capsular
polysaccharides in Escherichia coli. Annu. Rev. Biochem. 75, 39–68. doi:
10.1146/annurev.biochem.75.103004.142545
Zogaj, X., and Klose, K. E. (2010). Genetic manipulation of Francisella tularensis.
Front. Microbiol. 1:142. doi: 10.3389/fmicb.2010.00142
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Rasmussen, Fletcher, Long, Allen and Jones. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 14 May 2015 | Volume 6 | Article 338
